Journal Mobile Options
Table of Contents
Vol. 82, No. 4, 2009
Issue release date: June 2009
Urol Int 2009;82:448–452

Paratesticular Sarcomas in Brazil

Korkes F. · Castro M.G. · Romero F.R. · Godoy G. · Amary M.F. · Fernandes R.C. · Perez M.D.
Division of Urology and Department of Pathology, Medical School of Santa Casa of São Paulo, São Paulo, Brazil

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Purpose: Paratesticular sarcomas are rare and frequently reported as isolated case reports. Studies evaluating the relative frequency of the paratesticular sarcomas are limited, and to the best of our knowledge, this is the first study of paratesticular sarcomas in the Brazilian population. Patients and Methods: Medical records of all patients undergoing treatment for paratesticular sarcomas between 1993 and 2006 were retrieved from the archives of our institution. Results: Complete data from 12 patients (39 ± 23 years, range 13–78) with paratesticular sarcomas were available, which represented 6.7% of all orchiectomies performed for testicular malignancies in the same period. At the time of diagnosis, 3 patients had retroperitoneal spread of the disease, all of which had elevated serum lactic dehydrogenase levels. The remaining 9 patients had normal serum markers. There were 6 rhabdomyosarcomas, 4 leiomyosarcomas, 1 liposarcoma and 1 undifferentiated sarcoma. Median follow-up was 31.4 months. Primary surgical excision by inguinal approach was performed in all cases (radical orchiectomy in 10 and preservation of the testis in 2). Retroperitoneal lymph node dissection was performed in 3 patients and excision of the hemiscrotum in 1. Eight patients received adjuvant chemotherapy. Mean overall survival time was 27.8 ± 6.2 months after orchiectomy. Conclusion: Patients with paratesticular sarcomas are at high risk of disease progression, and systemic relapse remains a significant problem, determining poor prognosis. The high risk of local recurrence demands long-term follow-up, and intraoperative frozen section analysis might be of benefit. Elevated lactic dehydrogenase might also be a marker of retroperitoneal disease and poor prognosis. Improvement in survival requires effective systemic adjuvant therapy.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Radouane B, El Fenni J, Chaouir S, et al: Paratesticular rhabdomyosarcoma. A case report. J Radiol 2004;85:779–781.
  2. Mondaini N, Palli D, Saieva C, et al: Clinical characteristics and overall survival in genitourinary sarcomas treated with curative intent: a multicenter study. Eur Urol 2005;47: 468–473.
  3. Mora Nadal JI, Ponce Campuzano A, Llopis Manzanera J, et al: Paratesticular rhabdomyosarcoma. Actas Urol Esp 2004;28:245–248.
  4. Stewart RJ, Martelli H, Oberlin O, et al: Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J Clin Oncol 2003;21:793–798.
  5. Ferrari A, Bisogno G, Casanova M, et al: Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J Clin Oncol 2002;20:449–455.
  6. Stevens MC, Rey A, Bouvet N, et al: Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005;23:2618–2628.
  7. Fisher C, Goldblum JR, Epstein JI, et al: Leiomyosarcoma of the paratesticular region: a clinicopathologic study. Am J Surg Pathol 2001;25:1143–1149.
  8. Montgomery E, Fisher C: Paratesticular liposarcoma: a clinicopathologic study. Am J Surg Pathol 2003;27:40–47.
  9. Soosay GN, Parkinson MC, Paradinas J, et al: Paratesticular sarcomas revisited: a review of cases in the British Testicular Tumour Panel and Registry. Br J Urol 1996;77:143–146.
  10. Schwartz SL, Swierzewski SJ 3rd, Sondak VK, et al: Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. J Urol 1995;153:154–157.
  11. Catton CN, Cummings BJ, Fornasier V, et al: Adult paratesticular sarcomas: a review of 21 cases. J Urol 1991;146:342–345.
  12. Dotan ZA, Tal R, Golijanin D, et al: Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol 2006; 176:2038–2039.

    External Resources

  13. Hermans BP, Foster RS, Bihrle R, et al: Is retroperitoneal lymph node dissection necessary for adult paratesticular rhabdomyosarcoma? J Urol 1998;160:2074–2077.
  14. Emerson RE, Ulbright TM: Morphological approach to tumours of the testis and paratestis. J Clin Pathol 2007;60:866–880.
  15. Sesterhenn IA, Davis CJ Jr: Pathology of germ cell tumors of the testis. Cancer Control 2004;11:374–387.

    External Resources

  16. Lopes RI, Leite KR, Lopes RN: Paratesticular leiomyosarcoma treated by enucleation. Int Braz J Urol 2006;32:66–67.
  17. Connolly SS, D’Arcy FT, Bredin HC, et al: Value of frozen section analysis with suspected testicular malignancy. Urology 2006; 67:162–165.
  18. Enoch S, Wharton SM, Murray DS: Management of leiomyosarcomas of the spermatic cord: the role of reconstructive surgery. World J Surg Oncol 2005;3:23–24.
  19. Bacci G, Ferrari S, Longhi A, et al: Prognostic significance of serum LDH in Ewing’s sarcoma of bone. Oncol Rep 1999;6:807–811.
  20. Blyth B, Mandell J, Bauer SB, et al: Paratesticular rhabdomyosarcoma: results of therapy in 18 cases. J Urol 1990;144:1450–1453.
  21. Catton C, Jewett M, O’Sullivan B, et al: Paratesticular sarcoma: failure patterns after definitive local therapy. J Urol 1999;161:1844–1847.
  22. Khoubehi B, Mishra V, Ali M, et al: Adult paratesticular tumours. BJU Int 2002;90: 707–715.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50